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Dominant optic atrophyThe studies addressing themolecular mechanisms governingmitochondrial fusion and ﬁssion have brought
to light a small group of dynamin-like GTPases (Guanosine-Triphosphate hydrolase) as central regulators of
mitochondrial morphology and cristae remodeling, apoptosis, calcium signaling, and metabolism. One of
them is the mammalian OPA1 (Optic atrophy 1) protein, which resides inside the mitochondrion anchored
to the inner membrane and, in a cleaved form, is associated to oligomeric complexes, in the intermembrane
space of the organelle. Here, we review the studies that have made OPA1 emerge as the best understood
regulator of mitochondrial inner membrane fusion and cristae remodeling. Further, we re-examine the
ﬁndings behind the recent claim that OPA1 mediates adrenergic control of lipolysis by functioning as a
cytosolic A-kinase anchoring protein (AKAP), on the hemimembrane that envelops the lipid droplet. This
article is part of a Special Issue entitled: Mitochondrial dynamics and physiology.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial morphology varies according to cell type and cellu-
lar context from an interconnected ﬁlamentous network to isolated
dots. This morphological plasticity depends on both cytoskeletons
that control mitochondrial distribution andmotility [1], and on another
recently discovered parameter: mitochondrial dynamics. This phenom-
enon is due to a dynamic balance between antagonistic forces of ﬁssion
and fusion acting on mitochondrial membranes, which depend on pro-
tein complexes conserved throughout evolution [2]. When fusion takes
over ﬁssion, mitochondria appear as an interconnected network of ﬁla-
ments, while they turn into isolated dots when ﬁssion prevails. Several
proteins that control mitochondrial outer membrane ﬁssion have been
characterized. DRP1 FIS1 and MFF are key actors of its ﬁssion while the
mitofusins (MFN1 and MFN2) control its fusion. Few actors are known
to control the inner membrane dynamics, of which OPA1, the object
of this review, was ﬁrst identiﬁed as a profusion protein and later as
an actor of apoptosis and mtDNA maintenance.
The functional relevance of mitochondrial dynamics is empha-
sized by its repercussions in the main functions of the organelle (res-
piration, calcium homeostasis, ROS production and apoptosis), and by
its requirement during embryonic development. Knocking out MFN1,
MFN2, DRP1 or homozygous mutations of OPA1, leads to a lethalMitochondrial dynamics and
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l rights reserved.embryonic phenotype in mice [3–7]. Furthermore, a deﬁnite proof
for a major role of mitochondrial dynamics came from the unraveling
of neurodegenerative pathologies triggered by mutations in key
actors of this process. Mutations in MFN2 and OPA1 are respectively
responsible for type 2A Charcot–Marie–Tooth diseases and type 1
dominant optic atrophy (ADOA1) [8,9]. To what extent OPA1
functions are altered by pathogenic mutations of OPA1 leading to
ADOA1 will be discussed here.
1.1. OPA1, a mitochondrial dynamin
OPA1, was identiﬁed “in silico” as a human homolog of Mgm1p in
Saccharomyces cerevisiae and Msp1p in Schizosaccharomyces pombe,
and its mutations were found responsible for an optic neuropathy [8].
Human OPA1 ORF is built from 30 exons, 3 of which (4, 4b and 5b) are
alternatively spliced leading to 8mRNA [10].While exon 4 is evolution-
arily conserved, both exons 4b and 5b are speciﬁc to vertebrates [11].
The OPA1 gene encodes a mitochondrial protein that belongs to the
dynamins' family [8,12]; with which it shares three conserved regions:
a GTPase domain, a middle domain, and a GTPase effector domain
(GED) containing a coiled-coil domain (CC2) (Fig. 1). CC2, as well as
another distinct coiled-coil domain (CC1) located downstream the alter-
natively spliced region, could be responsible for the formation of
homotypic complexes between distinct OPA1 molecules [13]. On the
contrary, a coiled-coil domain (CC0) located in exon 5b has been
involved in hetero-interaction with CC1. Interestingly, recombinant
short isoform of OPA1 (discussed below) assembles into higher order
oligomers on the surface of cardiolipin-containing liposomes [14]. The
amino-terminal region of OPA1, preceding the GTPase domain, displays
MIS GTPase Middle GED
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Fig. 1. Schematic representation of OPA1 structure. OPA1 shares several structural features with dynamins. These include a GTPase domain containing the three consensus GTP
binding sequences (red bars) and the dynamin signature (red hatched bar), a middle domain and a GTPase effector domain (GED) containing a coiled-coil region (CCII). Before
the GTPase domain, Opa1 displays a mitochondrial import sequence (MIS) followed by a predicted transmembrane region (TM1), hydrophobic segments (TM2a and TM2b), and
coiled-coil regions (CC). These domains are found in OPA1 all splice variants while TM2a, TM2b, and CC-0 are only present in spliced exons 4b and 5b. OPA1 exons (numbers) are
schematized by double arrow. Intra-mitochondrial proteolytic cleavage sites for mitochondrial processing peptidase (MPP), paraplegin (S1) and YME1L (S2) are indicated.
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membrane helix (TM1) that is conserved in all OPA1 homologs. Two ad-
ditional hydrophobic domains are present, TM2a and TM2b, and they
are encoded by alternatively spliced exons 4b and 5b.
Precursors translated from the 8 OPA1 mRNA are targeted to mito-
chondria via theirMIS, which is removed upon import by themitochon-
drial processing peptidase (MPP) to give rise to long isoforms of the
GTPase that are collectively termed l-OPA1 [15,16]. Each l-OPA1 isoform
might then be subjected to a distinct proteolytic processing that gener-
ates short isoforms termed s-OPA1 [17]. Both short and long isoforms of
OPA1 are localized in the IMS and are associated with mitochondrial
membranes. It is proposed that l-OPA1 is anchored to the IM while
s-OPA1, lacking TM1, is peripherally attached to the IM, a fraction of it
having the possibility to diffuse in the IMS and to associate, within
this compartment, to the OM [15,16,18–20]. Accordingly, recombinant
s-OPA1 was recently found to be able to associate with liposomes
containing negatively charged phospholipids such as cardiolipin [14].
Numerous and discordant studies on the generation of s-OPA1 have im-
plicated three mitochondrial proteases recognizing two cleavage sites.
The rhomboid protease PARL, the mammalian counterpart of Pcp1p
that cleaves Mgm1p and Msp1p [21,22], is involved in the generation
of a low abundant soluble isoform of OPA1 in the IMS [20]. Based on
an overexpression study, the mAAA-protease paraplegin is proposed
to cleave OPA1 at S1 [19] (Fig. 1). However neither PARL nor paraplegin
dowholly explain the processing of OPA1 since their knockdown/out do
not affect the ratio of l- to s-isoforms of the dynamin [19,23–25]. Fur-
thermore, contribution in OPA1 processing of two other subunits of
them-AAA complex, AFG3L1 and AFG3L2,was revealed by experiments
conducted in yeast [23], and the i-AAA protease YME1L was shown to
be responsible for cleavage at S2 (Fig. 1), and other sites in mammals
[17,24]. No implication of m-AAA proteases in Mgm1p processing has
been shown while m-AAA-paraplegin was involved in the stability of
the long form of Msp1p [21,22]. Inducible OMA1-mediated cleavage of
OPA1, that was evidenced both ex vivo and in vivo, will be discussed
later (see Section 2.4).2. Functions and regulation of OPA1
2.1. Mitochondrial fusion
Loss of function of OPA1 by RNAi or gene knock-out, and of its
yeast orthologs, causes fragmentation of the tubular mitochondrial
reticulum [18,26–29]. Conversely, overproduction of this protein
promotes mitochondrial elongation in cells where mitochondria
are punctuated [15,30]. Interestingly, this effect is not observed in
Mfn1−/−cells, indicating that the fusogenic activity of OPA1 requires
MFN1, while MFN2 is dispensable. The profusion activity of OPA1 is
further conﬁrmed by experiments showing that mitochondrial fu-
sion is impaired in OPA1-depleted or OPA1−/− cells [17,29–32].It has been initially proposed that long forms of the dynamin are re-
sponsible for OPA1-mediated mitochondrial fusion while short forms
are unable to fusemitochondria [19,24,25,33]. However, this hypothesis
has not been then fully conﬁrmed by elegant studies in OPA1−/− cells
[17]. Splicing variants that produce both l- and s-OPA1 have indeed
the capacity to restore defective mitochondrial fusion in OPA1−/−
cells, while those that only produce s-OPA1 do not. However a
non-cleavable form of OPA1 is not able to induce fusion in OPA1−/−
cells and short forms can restore the capacity of this isoform tomediate
fusion.
The long and short forms of OPA1 function together in fusion, but
with distinct roles. In yeast, the IM-bound long form seems to anchor
to the membrane the short form, which lacks the transmembrane
domain. Noteworthy, mitochondrial fusion requires a functional
GTPase domain only in the short form of Mgm1p, but not in
the long form of the dynamin [34–36]. However, in mammals
this mechanism could be different because the GTPase activity
(and GED domain) of OPA1 is essential for the fusogenic function
of the dynamin [30].
Consistent with its localization inside the organelle, OPA1 primary
function is the fusion of the inner membrane. Knockout of OPA1 does
not abolish OM fusion ex vivo and accumulation of multi-matrix
structures reﬂecting fusion of OM without that of IM has been re-
vealed by electron microscopy in OPA1−/− cells [29]. However,
while mitochondria depleted from Mgm1p cannot fuse their IM,
they are competent for OM fusion in vitro but not in vivo [36],
suggesting that fusion of OM and IM is not as tightly coupled in mam-
mals as it seems to be in yeast. Furthermore OPA1 is needed only on
onemitochondrion to promote fusion between two adjacentmitochon-
dria ex vivo while in vitro Mgm1p is required on both mitochondria for
efﬁcient fusion [29,36]. Recently, in vitro experiments showing that re-
combinant s-OPA1 alone tubulates liposomes containing cardiolipin,
offer the ﬁrst mechanistic description of the fusogenic function of the
dynamin [14]. OPA1may protrude themitochondrial inner membranes
toward each other during the fusion process independent of its GTPase
activity. However recombinant s-OPA1 did not induce the fusion, either
in the presence or in the absence of GTP, of cardiolipin-containing lipo-
somes indicating that something ismissing in such assay such as l-OPA1
or other factors.2.2. IM structure, mtDNA maintenance and mitochondrial energetics
Electron microscopy analyses showed that fragmented mitochon-
dria fromOPA1-depleted cells have an altered internal structure [18,28].
OPA1 inactivation, through changes in IM morphology, could perturb
mtDNA anchoring to this membrane and impair its replication. Indeed,
missense mutations of OPA1 cause mtDNA deletions [37,38], and
down-regulation of OPA1 in HeLa cells was recently associated to loss
of mtDNA [39]. Loss of mitochondrial nucleoids and mtDNA was also
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maintenance agrees with earlier ﬁndings in yeast showing that inacti-
vation of Mgm1p andMsp1p leads tomtDNA depletion [42,43]. Impair-
ment of mtDNA synthesis, resulting in a reduction of the number of
molecules per cell at each cell division, was thus proposed. Beside the
inﬂuence of OPA1 in mtDNA replication through IM structuration, a di-
rect role of the dynamin in this processwas proposed by Elachouri et al.
[39]. In their model, OPA1 contributes to nucleoid attachment to the IM
through interactionswith IM-embedded exon 4b and promotesmtDNA
replication and distribution. However, inactivation of Dnm1p, the yeast
homolog of the mammalian ﬁssion protein DRP1, reverses both the
changes in the organization of the cristae and the loss of mtDNA seen
in MGM1-deleted yeast, suggesting that the role of Mgm1p in mtDNA
maintenance may be a secondary effect of its function in mitochondrial
fusion [44]. On the other hand, we were recently able to uncouple the
function of Msp1p in the control of mitochondrial morphology and
genome maintenance in S. pombe [45]. Inactivation of two OM integral
profusion proteins Fzo1p and Ugo1p in S. cerevisiae also causes frag-
mentation of mitochondria and loss of mtDNA in a DNM1+-dependent
manner [46,47]. MFN2 (one of the two human functional homologs of
Fzo1p) was also described as an indirect contributor to mtDNA integrity
and distribution inmammals [40,41]; here, impairment ofmitochondrial
fusion, which is thought to be important for the maintenance of the mi-
tochondrial functions by allowing the exchange of intra-mitochondrial
content, might increase mtDNA instability, thus preventing damaged
nucleoids from being repaired or complemented. The mechanism(s)
involved in mtDNA maintenance could be distinct in yeast and human,
and might be linked to the absence of the sequence encoded by exon 4b
of OPA1 in Mgm1p. Clearly, the molecular mechanisms that govern
mtDNA maintenance in link with mitochondrial dynamics are poorly
understood and constitute an important future challenge.
OPA1 inactivation through alterations in cristae morphology, the
major place of oxidative phosphorylation, could also lead to energetic
defects. Defective oxidative phosphorylation could also originate
from loss of mtDNA. Accordingly, RNAi depleted OPA1 cells show a
severe reduction of endogenous respiration, no stimulation upon ad-
dition of uncoupler and a diminution of oxygen consumption driven
by complexes I, II and IV [31]. Interactions between OPA1 and respira-
tory complexes I, II and III were revealed by immuno-precipitation,
suggesting that OPA1 could regulate oxidative phosphorylation by
stabilizing the mitochondrial respiratory chain complexes [48].
2.3. Apoptosis
In addition to mitochondrial fragmentation, down-regulation of
OPA1 increases cell sensitivity to spontaneous and induced apoptosis
[28,32,49,50]. On the contrary, over-expression of OPA1, by inhibiting
cytochrome c release, protects cells from apoptosis induced by intrin-
sic stimuli [50]. Interestingly, this effect is also observed in Mfn1−/−
and double Mfn1−/− and Mfn2−/− cells, indicating that OPA1 can
block apoptosis independently from its role in mitochondrial fusion.
Uncoupling of fusogenic and apoptotic functions of the dynamin is
also observed upon knock-down of particular OPA1 splice variants,
revealing that isoforms which contain exon 4 are important for mito-
chondrial fusion while those containing either exon 4b or exon 5b
regulate cytochrome c release [11].
Anti-apoptotic function of OPA1 was attributed to the formation of
OPA1-containing complexes that maintain the structure of the cristae
junctions and sequester cytochrome c within the cristal space [50,51].
Upon incubation of mitochondria with pro-apoptotic BH3-only pro-
teins, OPA1 complexes rapidly dissociate, leading to mobilization of
cytochrome c from the intracristal space to the IMS and subsequent
release through the OM into the cytosol. Over-expression of OPA1, or
a disassembly-resistant mutant of the dynamin, stabilizes such com-
plexes and inhibit tBid-induced cytochrome cmobilization and apopto-
sis. Involvement of OPA1 disassembly in cytochrome cmobilizationwasrecently shown to occur in BNIP3-induced apoptosis [52]. Interestingly,
thiswas shown to be dependent on the interaction of this pro-apoptotic
member of the BCL2 family with the dynamin. While these results indi-
cate that OPA1 assembly and disassembly regulate cytochrome c mobi-
lization, some controversies still persist concerning the relationships
between cristae remodeling, disassembly of OPA1 oligomers, and cyto-
chrome c mobilization (for discussion see [53,54]). In this context,
another role of OPA1 in cytochrome c release could be linked to the
fact that OPA1, like its yeast homolog [34], binds to cardiolipin [14], a
major phospholipid of the IM with a known function in retaining cyto-
chrome c on the IMS face of the IM. Consistent with this possibility,
ROS-mediated cardiolipin oxidation was proposed to induce detach-
ment of cytochrome c, providing an alternative mechanism to its mobi-
lization in IMS (reviewed in [55] and [56]).
Interestingly, a recent work unravels the role of OPA1 in a
non-classical death signaling pathway, excitotoxicity, a process
that occurs in neurons following over-activation of glutamate receptors
independent of Bax permeabilization of the OM. Here, up-regulation of
the dynamin was shown to be able to restore mitochondrial morpholo-
gy and to protect neurons against excitotoxic damage, while its down-
regulation reduces the pro-survival effect of a calpain inhibitor [57].
2.4. Regulation
OPA1 is ubiquitously expressed, with high mRNA expression levels
in retina, brain, liver, heart and pancreas; typically, all the 8 spliced
forms of the OPA1 transcripts are expressed, but the abundance of
each variant seems to be under tissue-speciﬁc control [8,10,13,58]. At
the protein level, the overall expression level of OPA1 and the l- and
s-OPA1 ratios are also under tissue-speciﬁc control [13,15]. Interesting-
ly, the level of OPA1 protein expression can differentially inﬂuence two
types of fusion: a “transient fusion” that results in rapid exchange of sol-
uble components without affecting the morphology of mitochondria
and a “complete fusion” that permits the exchange of all mitochondrial
components and affects mitochondrial morphology [59]. Furthermore,
in contrast to the requirement for a combination of long and short
forms in normal condition, stress-induced mitochondrial hyperfusion
relies only on l-OPA1 [60].
Besides constitutive processing, cleavage of l-OPA1 was also shown
to be induced by dissipation of mΔψ and apoptosis, and correlated
withmitochondrial fragmentation [19,24,25,33]. These inducible cleav-
ages are mediated ex vivo by a zinc metalloprotease called OMA1, po-
tentially at S1 site in exon 5 [61,62]. In vivo evidence that OMA1 plays
an essential role in proteolytic cleavage of OPA1 was recently given
[63]. OMA1was also involved in the shortening of the dynamin induced
by down-regulation of both AFG3L1 and AFG3L2 [62]. Surprisingly, in-
activation of these m-AAA proteases in MEF does not result in accumu-
lation of the longOPA1 isoform, as seen in yeast [23], but rather induced
proteolysis of the dynamin and destabilization of its long isoformwhen
cleavage at S1 is impaired [62]. This suggests, thatm-AAA protease con-
trols both cleavage and turn-over of OPA1. Since OMA1 was shown to
be activated upon attenuation of its proteolytic degradation [61], it is
tempting to implicate mAAA-proteases in the degradation of OMA1;
in such a scenario, OMA1 would be sequestered with m-AAA proteases
in prohibitin-induced membrane lipid microdomains [64]. However,
individual knock-down of paraplegin or AFG3L2 seems to have no
effect on OMA1 cleavage [61]. Cells in which OMA1 expression is
down-regulated recovered fusedmitochondriamore quickly than control
cells after CCCP treatment and became less sensitive to staurosporine-
induced apoptosis [61], suggesting that, in these conditions, OMA1
regulates the functions of the dynamin by modulating the abundance of
the l-isoform.
Prohibitins, that regulate the activity of m-AAA proteases, were
also shown to inﬂuence the processing of OPA1 [65]. Deletion of Phb2 in-
duced the selective loss of the long OPA1 isoform, resulting in aberrant
cristae morphology and impaired resistance toward apoptosis. A recent
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binding to prohibitin-1 and activating the proteolytic processing of
OPA1,which subsequently leads tomitochondrial fragmentation and ap-
optosis [66]. Aurilide is a cyclic depsipeptide isolated from the Japanese
seahare, Dolabella auricularia, and a potent cytotoxic molecule that acti-
vates apoptosis via the intrinsic pathway.
Another study has shown the role of the rhomboid protease PARL
[115] in the generation of a low abundant IMS-soluble form of OPA1
that forms a complexwith the IM-anchored long form of OPA1 tomain-
tain the integrity of the cristae junctions. Accordingly, loss of PARL-
generated s-OPA1 widens the cristae junction and augments the sensi-
tivity of PARL−/−MEFs to pro-apoptotic stimuli [20,50].
Altogether, these data reveal that OPA1 functions are tightly reg-
ulated by proteolytic processing. However, the impact of other
post-transcriptional and post-translational modiﬁcations is still little
documented. While different OPA1 isoforms were involved in either
pro-fusion or anti-apoptotic activities of the dynamin [11], the molecu-
lar mechanisms that control the alternative splicing of its mRNA are
largely unknown. Ubiquitination and O-GlcNAcetylation of OPA1 were
recently described following prolonged treatment of rat kidney proxi-
mal tubular cells by prostaglandin or in high-glucose cultured neonatal
cardic myocytes, respectively [67,68]. A fewmonths ago, levels of OPA1
were shown to be directly controlled by the ubiquitin ligase APC/CCDH1
during cell cycle exit/entry [69]. This elegant work points the role ofmi-
tochondrial dynamics and biogenesis as important components of
mechanisms that coordinate cell metabolism and proliferation. Clues
regarding the contribution of lipids to the regulation of OPA1 have re-
cently emerged in vitro by showing that s-OPA1 GTPase activity is stim-
ulated in cardiolipin-containing liposomes [14].
3. Physiopathological relevance of OPA1 functions
3.1. Effects of pathogenic mutations on OPA1 functions
Pathogenic OPA1 mutations account for about 60% of autosomal
dominant optic atrophy (ADOA), a common cause of inherited visual
failure, with a frequency of 1:10,000 to 1:50,000 [70]. Although optic
nerve degeneration remains the deﬁning feature of ADOA1, up to 20%
of patients with OPA1mutations also develop additional neuromuscular
complications (ADOA1+ syndrome), including deafness, ataxia, myopa-
thy, peripheral neuropathy and progressive external ophthalmoplegia
[71]. One could thus wonder to what extent does inactivation of OPA1
functions contributes to the ADOA1 and ADOA1+ pathogenesis.
Unlike the expression of wild-type OPA1 in OPA1-null MEF, that of
several OPA1 pathogenic mutants, associated with ADOA1 or ADOA1+,
did not restore tubular mitochondrial morphology, indicating a loss of
mitochondrial fusion activity [14]. In vitro assays revealed that these
ADOA1 alleles disrupt key biochemical features of OPA1.Most of GTPase
mutants showed reduced levels of stimulatedGTP hydrolysis under low
salt and in the presence of lipids, while a mutant in the P loop has both
complete loss of basal and stimulated GTPase activity. No effect on lipo-
somes was observed for GTPase mutants, contrarily to C-terminal mu-
tants, which failed to tubulate cardiolipin-containing liposomes with
or without defect in the binding of liposomes. This work suggests that
regulated GTPase activity as well as membrane binding and tubulation
is crucial for OPA1 function, but unfortunately doesn't clarify phenotype
and genotype ADOA1 relationships.
Numerous studies revealed thatﬁbroblasts ormyotubes fromADOA1
or ADOA1+ patients bear fragmented mitochondria [48,49,72–74].
Alteration of mitochondrial distribution has also been observed in
myotubes from ADOA1 patient, as well as in OPA1-silenced retinal
ganglionic cells (RGC), human neuroblastoma and hippocampal neu-
rons [73,75,76]. Interestingly, in RGC expressing OPA1 pathogenic mu-
tations, mitochondria are fragmented, less motile and accumulate in
the cell bodies (cited with permission [77]). RGC from adult heterozy-
gous OPA1 mutant mice show both increased levels of mitochondrialfragmentation and of autophagy [5,78]. Pathogenic mutations of OPA1
by impairing fusion and decreasing both OPA1 levels and mΔψ could
result in deregulated autophagy, which in turn contributes to the path-
ogenesis of ADOA1. It has indeed been recently shown that fragmented
mitochondria undergoing autophagy have reducedmΔψ and decreased
levels of OPA1 [79]. Furthermore, Gomes et al. recently described
that, in OPA1−/− cells, impairment of mitochondrial elongation
which is induced during autophagy as a protective mechanism,
leads to mitochondrial dysfunctions that ultimately result in cell
death [80].
Altogether, the above results suggest that alterations of mitochon-
drial distribution and morphology could contribute to ADOA1 patho-
genesis. However, some pathogenic OPA1 mutations did not change
mitochondrial morphology [72] but increased susceptibility to apopto-
sis [49]. Furthermore, in vivo impairment of oxidative phosphorylation
with lowered mitochondrial ATP production on muscle from ADOA1
patients, ﬁrst documented for a common GED micro-deletion, was fur-
ther extended to several OPA1mutations [81–83]. Interestingly, this de-
fect does not seem to be correlated withmtDNA alteration, cytochrome
c oxidase (COX)-negative ﬁber frequency, and occurs irrespective of
mutational subtypes and disease severity [84]. Defective mitochondrial
ATP synthesis was also documented in ﬁbroblasts and in lymphoblasts
frompatients carrying different OPA1mutations [48,72,74,85]. Interest-
ingly, in the latter case, this occurs only in patientswith poor vision [85].
Patients with relative preserved vision could maintain normal mito-
chondrial ATP synthesis rate through increased respiration. Such a com-
pensatory effect was earlier proposed, together with the hypothesis
that deﬁciency in COX activity might limit this possibility [72,86]. Ac-
cordingly, contrarily to patients who maintain normal vision, neither
speciﬁc activity of respiratory complexes nor respiration was modiﬁed
in patients with severe vision loss when compared to controls [85].
These observations support earlier results that failed to show defective
oxidative phosphorylation in mitochondria of lymphoblastoid cell lines
of patients from ADOA1 patients [87]; this study did not include ATP
production assay. Coupling defect of oxidative phosphorylation, with
reduced activity of complex IV and increased activity of complex V,
has been observed in ﬁbroblasts fromADOA1 andADOA1+ patients, as-
sociated or not with reduced mitochondrial ATP synthesis respectively
[72].
Multiple mitochondrial deletion and COX-negative ﬁbers, which
were ﬁrst described in ADOA1+ [37,38], were subsequently identiﬁed
in ADOA1 patients but at lower levels [84]. This observation impli-
cates a contributing role for secondary mtDNA defects in triggering
multi-systemic dysfunctions among affected OPA1 carriers. While de-
pletion of mitochondrial genome occurs in yeast, without at the pres-
ent time any evidence for mtDNA deletion, no mtDNA depletion was
reported in the skeletal muscle of patients carrying pathogenic OPA1
mutations [37,38,71]. On the contrary, a 2- to 4-fold increase in
mtDNA copy number was observed in COX-negative ﬁbers of both
ADOA1 and ADOA1+ patients, with greater mtDNA proliferation in
the latter case [84]. This increase could act as a compensatory mecha-
nism to maintain an adequate ATP level, but could also be detrimental
since mtDNA proliferation was linked with increased apoptosis suscep-
tibility [88]. Furthermore, low levels of wild-type (WT) mtDNA mole-
cules were present in cytochrome c oxydase deﬁcient ﬁbers and
clonal expansion of deleted mtDNA species was evidenced [84]. Com-
pensatory mitochondrial proliferation could thus lead to replication of
the mutant species at the expense of WT resulting in loss of COX activ-
ity. In blood lymphocytes or ﬁbroblasts from ADOA1 patients, earlier
works showed a slight reduction or no change of mtDNA copy number,
respectively [48,89].
Finally, invertebrate models bearing OPA1 mutations emphasize
the critical generation of ROS associated to OPA1 dysfunction.
Caenorhabditis elegans mutations of the OPA1 homolog, eat-3, cause
mitochondrial fragmentation as well as hypersensitivity to oxidative
stress but there is no evidence of increased cell death [90]. Homozygous
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glossy eye phenotypes in somatic clones of adult ﬂies by increased apo-
ptosis or increased ROS production, respectively [91]. Heterozygous
mutations result in a shortened lifespan, aberrant mitochondrial struc-
tures, increased production of ROS, sensitivity to oxidative stress and
defects in activity of respiratory chain complexes [92,93]. These results
point to a possible involvement of oxidative stress in ADOA1 pathogen-
esis that must be evaluated in mammals with regard to its potential
therapeutic implications.3.2. Neurons and more
A few years ago, two murine models that recapitulate some crucial
features of ADOA1 in humans have been published [4,5] (see for re-
view [94]), promising to be very useful for the development of thera-
peutic strategies. These heterozygous mutant mice, carrying either a
premature stop codon (OPA1Q285STOP/+) or an in-frame deletion of
27 amino acids (OPA1Q329-355del/+) in the GTPase domain, are based
on haploinsufﬁciency since both models show a 50% reduction in
OPA1 protein expression. This observation supports, as evidenced in
human, haploinsufﬁciency as the main pathomechanism in ADOA1
[70]. However, we and others have proposed that, depending on the
mutation, dominant negative effects could cause the disease [49,70].
Both homozygous mutations are lethal at early stages of embryogen-
esis [4,5], and growth retardation, exencephaly and abnormal pat-
terning along the anterior–posterior axis were further evidenced in
a third mutant carrying an homozygous mutation in the middle do-
main [95].
Dendritic pruning of RGC was observed in a 10 month‐old
OPA1Q285STOP/+ mouse and this effect was exacerbated with age [96].
Marked changes in RGC connectivity were observed before optic
nerve structural alterations at the onset of visual defects, supporting
the development of RGC dysfunction as an early step in the patho-
physiology of ADOA1. This dendritic atrophy seems to result from re-
duction of synaptic density that was observed from a 12 month-old
and could originate from energetic failure [97]. Interestingly, the den-
dritic density of fragmented mitochondria in OPA1Q285STOP/+ mouse
was largely reduced, while their membrane potential was not signif-
icantly affected, suggesting that the energetic failure is due to altered
distribution. In this context, down-regulation of OPA1 in hippocampal
neurons also caused a reduction in mitochondrial density in neurites
and correlated with reduced spine density [76]. No signiﬁcant loss of
RGC can be detected in OPA1Q285STOP/+ mouse, at one year (or even
older) but functional deﬁcits are detectable with electroretinogram
[78,96,98]. However, this was not the case in the OPA1Q329-355del/+
mouse model, in which age-dependent loss of RGC and optic nerve
axons were observed [4,99]; the remaining RGC being functional. Re-
cent data conﬁrmed the retinal nerve ﬁber thinning in human, that
was evidenced 30 years ago in post-mortem histopathological studies
of two patients with ADOA1 [100]. Thus, RGC loss in ADOA1 is cer-
tainly a relevant mechanism but that can be neither the only one
nor the earliest.
Subtle systemic neurological neuromuscular and metabolic abnor-
malities were, in accordance with ADOA1+ syndrome in humans,
reported in both ADOA1 mouse models [4,5]. Furthermore, mice with
OPA1 deleted in pancreatic beta cells have impaired glucose-stimulated
ATP production and insulin secretion and thus develop hyperglycemia
[101]. This could be due to diminished levels of proteins and activity of
complex IV leading to respiratory defects and lowered ATP levels upon
glucose stimulation. Extra-ocular phenotypes, such as heart and skeletal
muscle dysfunctions, were also evidenced in heterozygous Drosophila
mutants [92,93]. In the heart, OPA1downregulationwas shown to induce
heart tube dilatation, profound contractile impairment [102], and to
alter cardiac adaptation to pressure overload [103]. Changes in OPA1
expression were evidenced in mouse neonatal cardiomyocytes exposedto high glucose that compromises myocardial contractile function, in a
rat model with heart failure and in failing human hearts [68,104].
4. OPA1 on the lipid droplets?
A recent study has described the presence of OPA1 outside of mi-
tochondria, namely in the lipid droplets (LDs) of the adipocyte; here,
the dynamin GTPase works as a A-kinase anchoring protein to ensure
a totally new function: lipolysis of the neutral lipids that are stored in
the LDs of the adipocytes [105].
The LD provide a cellular platform where excess fatty acids and
cholesterol are stored as neutral lipids, to be mobilized in response
to the energy and functional needs of the cell or of the organism
[106]. It consists of an organic core comprising neutral lipids (mainly
triacylglycerols and sterol esters) that is bounded by a monolayer of
phospholipids. A number of proteins are associated to the LDs, in-
cluding structural proteins (e.g. members of the perilipin family),
lipid-synthesis enzymes (e.g. acetyl-CoA carboxylase, acyl-CoA synthe-
tase and acyl-CoA:diacylglycerol acyltransferase-2), lipases (e.g. adi-
pose tissue triacylglycerol lipase), and membrane-trafﬁcking proteins.
In this context, the presence of mitochondrial proteins on the LD is un-
expected, although it should be also noted that secondary functions for
mitochondrial proteins on other cellular organelles have been reported.
Indeed, several actors of mitochondrial dynamics have also been found
to localize, albeit only in part, in other organelles such as peroxisomes
(DRP1, FIS1, MFF) and the endoplasmic reticulum (MFN2) [107,108].
However, in the study in object the majority of endogenous OPA1 was
present in LD fractions isolated from differentiated adipocytes, which
is unprecedented. In the adypocytes, LDs are physically associated to
mitochondria [109–113]; therefore, this ﬁnding could be explained by
considering the possibility that contaminating mitochondria were
present in the LD fraction analyzed. Indeed, their mass spectrometry
analysis revealed, in addition to OPA1, the presence of many other
mitochondrial proteins [105]. In this study, the authors report also the
localization of OPA1 on the LDs by ﬂuorescence microscopy; however,
because the majority of the adipocyte volume is occupied by LDs and
the two organelles are in physical contact, this data should be consid-
ered with caution.
The proposed presence of OPA1 on the LD raises the question of
what is the function of this mitochondrial fusion protein on this
organelle, and whether its function in LD biology requires or not
its dynamin GTPase activity. Pidoux and collaborators propose a
new role for OPA1 as a protein kinase A (PKA)-anchoring protein
(AKAP) for perilipin. Perilipin localizes on the phospholipid surface
of the LDs and serves as a gatekeeper to control access of lipases to
the lipids inside the LD. Activation of PKA and subsequent phosphor-
ylation of perilipin allow lipases to gain access to the lipid core of
the organelle, thereby promoting lipolysis on energy demands.
However, there is no evidence that a supercomplex that contains
OPA1, perilipin and PKA actually exists on the surface of the LD,
thereby leaving the proposed OPA1-perilipin model orphan of ex-
perimental validation.
Noteworthy to mention, silencing of OPA1 reduces induced lipol-
ysis within the differentiated adipocytes. To validate this ﬁnding,
the authors rescued this phenotype by over-expressing GFP-OPA1.
However, since this fusion protein cannot be imported in the mito-
chondrion, the claim that mitochondrial long and short forms of
OPA1 exit this organelle to be re-localized on the LD where they coor-
dinate lipogenesis is questionable. This point is of outstanding rele-
vance because doubts on the mechanism through which long and
short forms of OPA1 exit from the IM and the IMS of the organelle
to be anchored on the phospholipid monolayer of the LD put into
question also the claim that short-OPA1 is present on the LD: for in-
stance, which mitochondrial OPA1 protease would also be transported
on the LD, and how would its cleavage be regulated there if such
membrane-anchored protease cannot be inserted in a phospholipid
181P. Belenguer, L. Pellegrini / Biochimica et Biophysica Acta 1833 (2013) 176–183bilayer? Thus, one acceptable conclusion from the study in object is that
in an over-expression system a non-mitochondria imported/folded
chimeric GFP-OPA1 protein can affect lipolysis. It should be noted,
however, that to date no evidence links ADOA1 patients or mouse
models bearing OPA1 mutations to altered lipid metabolism, even
if in a recent publication the loss of the mitochondrial protease
OMA1, which alters the processing of OPA1 inside the mitochondria,
was shown to cause obesity in mice [63].
Thus, although this whole new topic is interesting, many ques-
tions and shadows remain to be addressed before accepting the local-
ization and role of OPA1 on the LDs. Clearly, future work will be
needed to continue to address the mechanism of crosstalks between
mitochondria and LDs.5. Concluding remarks and future challenges
Discovered in 2000 as a protein involved in the fusion of mito-
chondria, the molecular mechanisms that govern the fusogenic role
of OPA1 remain nevertheless little known. As member of the dynamin
family, OPA1 could act, like its yeast homolog, as a mechanoenzyme
moving closer together and merging mitochondrial IM membranes,
thanks to its capacity to oligomerize through GTP hydrolysis. However,
several data suggest that OPA1 could act on lipids to inﬂuence the orga-
nization of membranes, their ﬂuidity and their fusogenic properties. An
impressive number of studies concerning the role of OPA1 in apoptosis
were published since the initial discovery of its implication in this cell
death mechanism in 2003. This function, clearly independent from its
fusogenic role, is linked to the capacity of OPA1 to control themobiliza-
tion of cytochrome c in the IMS. Themolecular mechanisms involved in
this process have been characterized, and imply the formation of oligo-
mers of OPA1 that hold the hemoprotein in the intra-cristae compart-
ment. Nevertheless, the interaction between OPA1 and cardiolipin, as
well as the effect of OPA1 inactivation on ROS production, together
asks the question of their consequences on cytochrome c mobilization.
Several years after the characterization of its yeast homolog, OPA1 is
now known to be involved in the maintenance of mitochondrial
genome by a mechanism that still remains to clarify. Does it involve a
direct role of OPA1 in anchoring mtDNA into the IM or is it a secondary
consequence of OPA1 fusogenic function?
To what extent inactivation of OPA1 functions contributes to
ADOA1 and ADOA1+ pathogenesis has yet to be elucidated. Data
on non-neuronal cell lines such as HeLa cells or MEFs or on skin-
ﬁbroblasts from ADOA1 or ADOA1+ patients suggest that impairment
of mitochondrial morphology, distribution and functions, as well as
more recently autophagy, could be involved alone or in combination.
It will be of great interest to address now the question in neurons.
In agreement with the identiﬁcation of the syndromic form of
ADOA1, recent studies have shown that the inactivation of OPA1
can also affect other tissues and organs than the optic nerve. The
publication during the revision process of this review of the implica-
tion of OPA1 in steroidogenesis in trophoblasts reinforces this no-
tion [114]. Nevertheless, until now, all the effects of OPA1 were
attributed to its role within the mitochondrion, with the exception
of its effect on lipolysis that could open a new ﬁeld of investigation
for this fascinating protein of which we are far from having exam-
ined from all angles.Acknowledgements
PB thanks her team andM.C.Miquel for correction of themanuscript.
PB was supported by grants from CNRS, the Université Paul Sabatier,
Rétina-France, AFM, AMMI, Ligue Contre le Cancer, UNADEV, ARC, and
Région Midi-Pyrénées. LP thanks past and present members of his lab;
work in his lab has been supported by CIHR (MOP-82718) and FRSQ.References
[1] I.R. Boldogh, L.A. Pon,Mitochondria on themove, Trends Cell Biol. 17 (2007) 502–510.
[2] B. Westermann, Mitochondrial fusion and ﬁssion in cell life and death, Nat. Rev.
Mol. Cell Biol. 11 (2010) 872–884.
[3] H. Chen, S.A. Detmer, A.J. Ewald, E.E. Grifﬁn, S.E. Fraser, D.C. Chan, Mitofusins
Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential
for embryonic development, J. Cell Biol. 160 (2003) 189–200.
[4] M.V. Alavi, S. Bette, S. Schimpf, F. Schuettauf, U. Schraermeyer, H.F. Wehrl, L.
Ruttiger, S.C. Beck, F. Tonagel, B.J. Pichler, M. Knipper, T. Peters, J. Laufs, B.
Wissinger, A splice site mutation in the murine Opa1 gene features pathology
of autosomal dominant optic atrophy, Brain 130 (2007) 1029–1042.
[5] V.J. Davies, A.J. Hollins, M.J. Piechota, W. Yip, J.R. Davies, K.E. White, P.P. Nicols,
M.E. Boulton, M. Votruba, Opa1 deﬁciency in a mouse model of autosomal dom-
inant optic atrophy impairs mitochondrial morphology, optic nerve structure
and visual function, Hum. Mol. Genet. 16 (2007) 1307–1318.
[6] J. Wakabayashi, Z. Zhang, N. Wakabayashi, Y. Tamura, M. Fukaya, T.W. Kensler,
M. Iijima, H. Sesaki, The dynamin-related GTPase Drp1 is required for embryonic
and brain development in mice, J. Cell Biol. 186 (2009) 805–816.
[7] N. Ishihara, M. Nomura, A. Jofuku, H. Kato, S.O. Suzuki, K. Masuda, H. Otera, Y.
Nakanishi, I. Nonaka, Y. Goto, N. Taguchi, H. Morinaga, M. Maeda, R.
Takayanagi, S. Yokota, K. Mihara, Mitochondrial ﬁssion factor Drp1 is essential
for embryonic development and synapse formation in mice, Nat. Cell Biol. 11
(2009) 958–966.
[8] C. Delettre, G. Lenaers, J.M. Griffoin, N. Gigarel, C. Lorenzo, P. Belenguer, L. Pelloquin,
J. Grosgeorge, C. Turc-Carel, E. Perret, C. Astarie-Dequeker, L. Lasquellec, B. Arnaud,
B. Ducommun, J. Kaplan, C.P. Hamel, Nuclear gene OPA1, encoding a mitochondrial
dynamin-related protein, is mutated in dominant optic atrophy, Nat. Genet. 26
(2000) 207–210.
[9] S. Zuchner, I.V. Mersiyanova, M. Muglia, N. Bissar-Tadmouri, J. Rochelle, E.L.
Dadali, M. Zappia, E. Nelis, A. Patitucci, J. Senderek, Y. Parman, O. Evgrafov, P.D.
Jonghe, Y. Takahashi, S. Tsuji, M.A. Pericak-Vance, A. Quattrone, E. Battaloglu,
A.V. Polyakov, V. Timmerman, J.M. Schroder, J.M. Vance, E. Battologlu, Mutations
in the mitochondrial GTPase mitofusin 2 cause Charcot–Marie–Tooth neuropa-
thy type 2A, Nat. Genet. 36 (2004) 449–451.
[10] C. Delettre, J.M. Griffoin, J. Kaplan, H. Dollfus, B. Lorenz, L. Faivre, G. Lenaers, P.
Belenguer, C.P. Hamel, Mutation spectrum and splicing variants in the OPA1
gene, Hum. Genet. 109 (2001) 584–591.
[11] A. Olichon, G. Elachouri, L. Baricault, C. Delettre, P. Belenguer, G. Lenaers, OPA1
alternate splicing uncouples an evolutionary conserved function in mitochon-
drial fusion from a vertebrate restricted function in apoptosis, Cell Death Differ.
14 (2007) 682–692.
[12] G.J. Praefcke, H.T. McMahon, The dynamin superfamily: universal membrane
tubulation and ﬁssion molecules? Nat. Rev. Mol. Cell Biol. 5 (2004) 133–147.
[13] V.R. Akepati, E.C. Muller, A. Otto, H.M. Strauss, M. Portwich, C. Alexander, Char-
acterization of OPA1 isoforms isolated from mouse tissues, J. Neurochem. 106
(2008) 372–383.
[14] T. Ban, J.A. Heymann, Z. Song, J.E. Hinshaw, D.C. Chan, OPA1 disease alleles caus-
ing dominant optic atrophy have defects in cardiolipin-stimulated GTP hydroly-
sis and membrane tubulation, Hum. Mol. Genet. 19 (2010) 2113–2122.
[15] A. Olichon, L.J. Emorine, E. Descoins, L. Pelloquin, L. Brichese, N. Gas, E. Guillou, C.
Delettre, A. Valette, C.P. Hamel, B. Ducommun, G. Lenaers, P. Belenguer, The
human dynamin-related protein OPA1 is anchored to the mitochondrial inner
membrane facing the inter-membrane space, FEBS Lett. 523 (2002) 171–176.
[16] M. Satoh, T. Hamamoto, N. Seo, Y. Kagawa, H. Endo, Differential sublocalization
of the dynamin-related protein OPA1 isoforms in mitochondria, Biochem.
Biophys. Res. Commun. 300 (2003) 482–493.
[17] Z. Song, H. Chen, M. Fiket, C. Alexander, D.C. Chan, OPA1 processing controls mi-
tochondrial fusion and is regulated by mRNA splicing, membrane potential, and
Yme1L, J. Cell Biol. 178 (2007) 749–755.
[18] L. Griparic, N.N. van der Wel, I.J. Orozco, P.J. Peters, A.M. van der Bliek, Loss of the
intermembrane space proteinMgm1/OPA1 induces swelling and localized constric-
tions along the lengths of mitochondria, J. Biol. Chem. 279 (2004) 18792–18798.
[19] N. Ishihara, Y. Fujita, T. Oka, K. Mihara, Regulation of mitochondrial morphology
through proteolytic cleavage of OPA1, EMBO J. 25 (2006) 2966–2977.
[20] S. Cipolat, T. Rudka, D. Hartmann, V. Costa, L. Serneels, K. Craessaerts, K. Metzger,
C. Frezza, W. Annaert, L. D'Adamio, C. Derks, T. Dejaegere, L. Pellegrini, R.
D'Hooge, L. Scorrano, B. De Strooper, Mitochondrial rhomboid PARL regulates
cytochrome c release during apoptosis via OPA1-dependent cristae remodeling,
Cell 126 (2006) 163–175.
[21] M. Herlan, F. Vogel, C. Bornhovd, W. Neupert, A.S. Reichert, Processing of Mgm1 by
the rhomboid-type protease Pcp1 is required for maintenance of mitochondrial
morphology and of mitochondrial DNA, J. Biol. Chem. 278 (2003) 27781–27788.
[22] I. Leroy, F. Khosrobakhsh, A. Diot, M. Daloyau, L. Arnaune-Pelloquin, C. Cavelier,
L.J. Emorine, P. Belenguer, Processing of the dynamin Msp1p in S. pombe reveals
an evolutionary switch between its orthologs Mgm1p in S. cerevisiae and OPA1
in mammals, FEBS Lett. 584 (2010) 3153–3157.
[23] S. Duvezin-Caubet, M. Koppen, J. Wagener, M. Zick, L. Israel, A. Bernacchia, R.
Jagasia, E.I. Rugarli, A. Imhof, W. Neupert, T. Langer, A.S. Reichert, OPA1 process-
ing reconstituted in yeast depends on the subunit composition of the m-AAA
protease in mitochondria, Mol. Biol. Cell 18 (2007) 3582–3590.
[24] L. Griparic, T. Kanazawa, A.M. van der Bliek, Regulation of the mitochondrial
dynamin-like protein Opa1 by proteolytic cleavage, J. Cell Biol. 178 (2007) 757–764.
[25] O. Guillery, F. Malka, T. Landes, E. Guillou, C. Blackstone, A. Lombes, P. Belenguer,
D. Arnoult, M. Rojo, Metalloprotease-mediated OPA1 processing is modulated
by the mitochondrial membrane potential, Biol. Cell 100 (2008) 315–325.
182 P. Belenguer, L. Pellegrini / Biochimica et Biophysica Acta 1833 (2013) 176–183[26] E.D. Wong, J.A. Wagner, S.W. Gorsich, J.M. McCaffery, J.M. Shaw, J. Nunnari, The
dynamin-related GTPase, Mgm1p, is an intermembrane space protein required
for maintenance of fusion competent mitochondria, J. Cell Biol. 151 (2000)
341–352.
[27] E. Guillou, C. Bousquet, M. Daloyau, L.J. Emorine, P. Belenguer, Msp1p is an
intermembrane space dynamin-related protein that mediates mitochondrial fu-
sion in a Dnm1p-dependentmanner in S. pombe, FEBS Lett. 579 (2005) 1109–1116.
[28] A. Olichon, L. Baricault, N. Gas, E. Guillou, A. Valette, P. Belenguer, G. Lenaers,
Loss of OPA1 perturbates the mitochondrial inner membrane structure and in-
tegrity, leading to cytochrome c release and apoptosis, J. Biol. Chem. 278
(2003) 7743–7746.
[29] Z. Song, M. Ghochani, J.M. McCaffery, T.G. Frey, D.C. Chan, Mitofusins and OPA1
mediate sequential steps in mitochondrial membrane fusion, Mol. Biol. Cell 20
(2009) 3525–3532.
[30] S. Cipolat, O.M. de Brito, B. Dal Zilio, L. Scorrano, OPA1 requires mitofusin 1 to
promote mitochondrial fusion, Proc. Natl. Acad. Sci. U. S. A. 101 (2004)
15927–15932.
[31] H. Chen, A. Chomyn, D.C. Chan, Disruption of fusion results in mitochondrial het-
erogeneity and dysfunction, J. Biol. Chem. 280 (2005) 26185–26192.
[32] Y.J. Lee, S.Y. Jeong, M. Karbowski, C.L. Smith, R.J. Youle, Roles of the Mammalian
mitochondrial ﬁssion and fusion mediators ﬁs1, drp1, and opa1 in apoptosis,
Mol. Biol. Cell 15 (2004) 5001–5011.
[33] S. Duvezin-Caubet, R. Jagasia, J. Wagener, S. Hofmann, A. Trifunovic, A. Hansson,
A. Chomyn, M.F. Bauer, G. Attardi, N.G. Larsson, W. Neupert, A.S. Reichert, Pro-
teolytic processing of OPA1 links mitochondrial dysfunction to alterations in mi-
tochondrial morphology, J. Biol. Chem. 281 (2006) 37972–37979.
[34] R.M. DeVay, L. Dominguez-Ramirez, L.L. Lackner, S. Hoppins, H. Stahlberg, J.
Nunnari, Coassembly of Mgm1 isoforms requires cardiolipin and mediates mito-
chondrial inner membrane fusion, J. Cell Biol. 186 (2009) 793–803.
[35] M. Zick, S. Duvezin-Caubet, A. Schafer, F. Vogel, W. Neupert, A.S. Reichert, Dis-
tinct roles of the two isoforms of the dynamin-like GTPase Mgm1 in mitochon-
drial fusion, FEBS Lett. 583 (2009) 2237–2243.
[36] S. Meeusen, R. DeVay, J. Block, A. Cassidy-Stone, S. Wayson, J.M. McCaffery, J.
Nunnari, Mitochondrial inner-membrane fusion and crista maintenance re-
quires the dynamin-related GTPase Mgm1, Cell 127 (2006) 383–395.
[37] P. Amati-Bonneau, M.L. Valentino, P. Reynier, M.E. Gallardo, B. Bornstein, A.
Boissiere, Y. Campos, H. Rivera, J.G. de la Aleja, R. Carroccia, L. Iommarini, P.
Labauge, D. Figarella-Branger, P. Marcorelles, A. Furby, K. Beauvais, F. Letournel, R.
Liguori, C. La Morgia, P. Montagna, M. Liguori, C. Zanna, M. Rugolo, A. Cossarizza,
B. Wissinger, C. Verny, R. Schwarzenbacher, M.A. Martin, J. Arenas, C. Ayuso, R.
Garesse, G. Lenaers, D. Bonneau, V. Carelli, OPA1 mutations induce mitochondrial
DNA instability and optic atrophy ‘plus’ phenotypes, Brain 131 (2008) 338–351.
[38] G. Hudson, P. Amati-Bonneau, E.L. Blakely, J.D. Stewart, L. He, A.M. Schaefer, P.G.
Grifﬁths, K. Ahlqvist, A. Suomalainen, P. Reynier, R. McFarland, D.M. Turnbull,
P.F. Chinnery, R.W. Taylor, Mutation of OPA1 causes dominant optic atrophy
with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial
DNA deletions: a novel disorder of mtDNA maintenance, Brain 131 (2008)
329–337.
[39] G. Elachouri, S. Vidoni, C. Zanna, A. Pattyn, H. Boukhaddaoui, K. Gaget, P.
Yu-Wai-Man, G. Gasparre, E. Sarzi, C. Delettre, A. Olichon, D. Loiseau, P.
Reynier, P.F. Chinnery, A. Rotig, V. Carelli, C.P. Hamel, M. Rugolo, G. Lenaers,
OPA1 links human mitochondrial genome maintenance to mtDNA replication
and distribution, Genome Res. 21 (2011) 12–20.
[40] H. Chen, J.M. McCaffery, D.C. Chan, Mitochondrial fusion protects against
neurodegeneration in the cerebellum, Cell 130 (2007) 548–562.
[41] H. Chen, M. Vermulst, Y.E. Wang, A. Chomyn, T.A. Prolla, J.M. McCaffery, D.C.
Chan, Mitochondrial fusion is required for mtDNA stability in skeletal muscle
and tolerance of mtDNA mutations, Cell 141 (2010) 280–289.
[42] B.A. Jones, W.L. Fangman, Mitochondrial DNA maintenance in yeast requires a
protein containing a region related to the GTP-binding domain of dynamin,
Genes Dev. 6 (1992) 380–389.
[43] L. Pelloquin, P. Belenguer, Y. Menon, B. Ducommun, Identiﬁcation of a ﬁssion
yeast dynamin-related protein involved in mitochondrial DNA maintenance,
Biochem. Biophys. Res. Commun. 251 (1998) 720–726.
[44] H. Sesaki, S.M. Southard, M.P. Yaffe, R.E. Jensen, Mgm1p, a dynamin-related
GTPase, is essential for fusion of the mitochondrial outer membrane, Mol. Biol.
Cell 14 (2003) 2342–2356.
[45] A. Diot, E. Guillou, M. Daloyau, L. Arnaune-Pelloquin, L.J. Emorine, P. Belenguer,
Transmembrane segments of the dynamin Msp1p uncouple its functions in
the control of mitochondrial morphology and genome maintenance, J. Cell Sci.
122 (2009) 2632–2639.
[46] H. Sesaki, R.E. Jensen, UGO1 encodes an outer membrane protein required for
mitochondrial fusion, J. Cell Biol. 152 (2001) 1123–1134.
[47] W. Bleazard, J.M. McCaffery, E.J. King, S. Bale, A. Mozdy, Q. Tieu, J. Nunnari, J.M.
Shaw, The dynamin-related GTPase Dnm1 regulates mitochondrial ﬁssion in
yeast, Nat. Cell Biol. 1 (1999) 298–304.
[48] C. Zanna, A. Ghelli, A.M. Porcelli, M. Karbowski, R.J. Youle, S. Schimpf, B.
Wissinger, M. Pinti, A. Cossarizza, S. Vidoni, M.L. Valentino, M. Rugolo, V.
Carelli, OPA1 mutations associated with dominant optic atrophy impair oxida-
tive phosphorylation and mitochondrial fusion, Brain 131 (2008) 352–367.
[49] A. Olichon, T. Landes, L. Arnaune-Pelloquin, L.J. Emorine, V. Mils, A. Guichet, C.
Delettre, C. Hamel, P. Amati-Bonneau, D. Bonneau, P. Reynier, G. Lenaers, P.
Belenguer, Effects of OPA1 mutations on mitochondrial morphology and apo-
ptosis: relevance to ADOA pathogenesis, J. Cell. Physiol. 211 (2007) 423–430.
[50] C. Frezza, S. Cipolat, O. Martins de Brito, M. Micaroni, G.V. Beznoussenko, T.
Rudka, D. Bartoli, R.S. Polishuck, N.N. Danial, B. De Strooper, L. Scorrano, OPA1controls apoptotic cristae remodeling independently from mitochondrial fusion,
Cell 126 (2006) 177–189.
[51] R. Yamaguchi, L. Lartigue, G. Perkins, R.T. Scott, A. Dixit, Y. Kushnareva, T.
Kuwana, M.H. Ellisman, D.D. Newmeyer, Opa1-mediated cristae opening is
Bax/Bak and BH3 dependent, required for apoptosis, and independent of Bak
oligomerization, Mol. Cell 31 (2008) 557–569.
[52] T. Landes, L.J. Emorine, D. Courilleau, M. Rojo, P. Belenguer, L. Arnaune-Pelloquin,
The BH3-only Bnip3 binds to the dynamin Opa1 to promote mitochondrial frag-
mentation and apoptosis by distinct mechanisms, EMBO Rep. 11 (2010) 459–465.
[53] L. Scorrano, Opening the doors to cytochrome c: changes in mitochondrial shape
and apoptosis, Int. J. Biochem. Cell Biol. 41 (2009) 1875–1883.
[54] R. Yamaguchi, G. Perkins, Dynamics of mitochondrial structure during apoptosis
and the enigma of Opa1, Biochim. Biophys. Acta 1787 (2009) 963–972.
[55] M. Ott, B. Zhivotovsky, S. Orrenius, Role of cardiolipin in cytochrome c release
from mitochondria, Cell Death Differ. 14 (2007) 1243–1247.
[56] Y.P. Ow, D.R. Green, Z. Hao, T.W. Mak, Cytochrome c: functions beyond respira-
tion, Nat. Rev. Mol. Cell Biol. 9 (2008) 532–542.
[57] A. Jahani-Asl, K. Pilon-Larose, W. Xu, J.G. MacLaurin, D.S. Park, H.M. McBride, R.S.
Slack, The mitochondrial inner membrane GTPase, optic atrophy 1 (Opa1), re-
stores mitochondrial morphology and promotes neuronal survival following
excitotoxicity, J. Biol. Chem. 286 (2011) 4772–4782.
[58] C. Alexander, M. Votruba, U.E. Pesch, D.L. Thiselton, S. Mayer, A. Moore, M.
Rodriguez, U. Kellner, B. Leo-Kottler, G. Auburger, S.S. Bhattacharya, B.
Wissinger, OPA1, encoding a dynamin-related GTPase, is mutated in autosomal
dominant optic atrophy linked to chromosome 3q28, Nat. Genet. 26 (2000)
211–215.
[59] X. Liu, D. Weaver, O. Shirihai, G. Hajnoczky, Mitochondrial ‘kiss-and-run’: inter-
play between mitochondrial motility and fusion-ﬁssion dynamics, EMBO J. 28
(2009) 3074–3089.
[60] D. Tondera, S. Grandemange, A. Jourdain, M. Karbowski, Y. Mattenberger, S.
Herzig, S. Da Cruz, P. Clerc, I. Raschke, C. Merkwirth, S. Ehses, F. Krause, D.C.
Chan, C. Alexander, C. Bauer, R. Youle, T. Langer, J.C. Martinou, SLP-2 is required
for stress-induced mitochondrial hyperfusion, EMBO J. 28 (2009) 1589–1600.
[61] B. Head, L. Griparic, M. Amiri, S. Gandre-Babbe, A.M. van der Bliek, Inducible pro-
teolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian
cells, J. Cell Biol. 187 (2009) 959–966.
[62] S. Ehses, I. Raschke, G. Mancuso, A. Bernacchia, S. Geimer, D. Tondera, J.C.
Martinou, B. Westermann, E.I. Rugarli, T. Langer, Regulation of OPA1 processing
and mitochondrial fusion by m-AAA protease isoenzymes and OMA1, J. Cell Biol.
187 (2009) 1023–1036.
[63] P.M. Quiros, A.J. Ramsay, D. Sala, E. Fernandez-Vizarra, F. Rodriguez, J.R. Peinado,
M.S. Fernandez-Garcia, J.A. Vega, J.A. Enriquez, A. Zorzano, C. Lopez-Otin, Loss of
mitochondrial protease OMA1 alters processing of the GTPase OPA1 and causes
obesity and defective thermogenesis in mice, EMBO J. 31 (2012) 2117–2133.
[64] H. McBride, V. Soubannier, Mitochondrial function: OMA1 and OPA1, the
grandmasters of mitochondrial health, Curr. Biol. 20 (2010) R274–R276.
[65] C. Merkwirth, T. Langer, Prohibitin function within mitochondria: essential roles
for cell proliferation and cristae morphogenesis, Biochim. Biophys. Acta 1793
(2009) 27–32.
[66] S. Sato, A. Murata, T. Orihara, T. Shirakawa, K. Suenaga, H. Kigoshi, M. Uesugi,
Marine natural product aurilide activates the OPA1-mediated apoptosis by bind-
ing to prohibitin, Chem. Biol. 18 (2011) 131–139.
[67] R. Kar, N. Mishra, P.K. Singha, M.A. Venkatachalam, P. Saikumar, Mitochondrial
remodeling following ﬁssion inhibition by 15d-PGJ2 involves molecular changes
in mitochondrial fusion protein OPA1, Biochem. Biophys. Res. Commun. 399
(2010) 548–554.
[68] A. Makino, J. Suarez, T. Gawlowski, W. Han, H. Wang, B.T. Scott, W.H. Dillmann,
Regulation of mitochondrial morphology and function by O-GlcNAcylation in
neonatal cardiac myocytes, Am. J. Physiol. Regul. Integr. Comp. Physiol. 300
(2011) R1296–R1302.
[69] A. Garedew, C. Andreassi, S. Moncada, Mitochondrial dynamics, biogenesis, and
function are coordinated with the cell cycle by APC/C CDH1, Cell Metab. 15
(2012) 466–479.
[70] P. Amati-Bonneau, D. Milea, D. Bonneau, A. Chevrollier, M. Ferre, V. Guillet,
N. Gueguen, D. Loiseau, M.A. de Crescenzo, C. Verny, V. Procaccio, G.
Lenaers, P. Reynier, OPA1-associated disorders: phenotypes and pathophys-
iology, Int. J. Biochem. Cell Biol. 41 (2009) 1855–1865.
[71] P. Yu-Wai-Man, P.G. Grifﬁths, G.S. Gorman, C.M. Lourenco, A.F. Wright, M.
Auer-Grumbach, A. Toscano, O. Musumeci, M.L. Valentino, L. Caporali, C.
Lamperti, C.M. Tallaksen, P. Duffey, J. Miller, R.G. Whittaker, M.R. Baker, M.J.
Jackson, M.P. Clarke, B. Dhillon, B. Czermin, J.D. Stewart, G. Hudson, P. Reynier, D.
Bonneau, W. Marques Jr., G. Lenaers, R. McFarland, R.W. Taylor, D.M. Turnbull, M.
Votruba, M. Zeviani, V. Carelli, L.A. Bindoff, R. Horvath, P. Amati-Bonneau, P.F.
Chinnery,Multi-systemneurological disease is common inpatientswithOPA1mu-
tations, Brain 133 (2010) 771–786.
[72] A. Chevrollier, V. Guillet, D. Loiseau, N. Gueguen, M.A. de Crescenzo, C. Verny, M.
Ferre, H. Dollfus, S. Odent, D. Milea, C. Goizet, P. Amati-Bonneau, V. Procaccio, D.
Bonneau, P. Reynier, Hereditary optic neuropathies share a common mitochon-
drial coupling defect, Ann. Neurol. 63 (2008) 794–798.
[73] M. Spinazzi, S. Cazzola, M. Bortolozzi, A. Baracca, E. Loro, A. Casarin, G. Solaini, G.
Sgarbi, G. Casalena, G. Cenacchi, A. Malena, C. Frezza, F. Carrara, C. Angelini, L.
Scorrano, L. Salviati, L. Vergani, A novel deletion in the GTPase domain of
OPA1 causes defects in mitochondrial morphology and distribution, but not in
function, Hum. Mol. Genet. 17 (2008) 3291–3302.
[74] P. Amati-Bonneau, A. Guichet, A. Olichon, A. Chevrollier, F. Viala, S. Miot, C.
Ayuso, S. Odent, C. Arrouet, C. Verny, M.N. Calmels, G. Simard, P. Belenguer, J.
183P. Belenguer, L. Pellegrini / Biochimica et Biophysica Acta 1833 (2013) 176–183Wang, J.L. Puel, C. Hamel, Y. Malthiery, D. Bonneau, G. Lenaers, P. Reynier, OPA1
R445H mutation in optic atrophy associated with sensorineural deafness, Ann.
Neurol. 58 (2005) 958–963.
[75] S. Kamei, M. Chen-Kuo-Chang, C. Cazevieille, G. Lenaers, A. Olichon, P. Belenguer,
G. Roussignol, N. Renard, M. Eybalin, A. Michelin, C. Delettre, P. Brabet, C.P.
Hamel, Expression of the opa1 mitochondrial protein in retinal ganglion cells:
its downregulation causes aggregation of the mitochondrial network, Invest.
Ophthalmol. Vis. Sci. 46 (2005) 4288–4294.
[76] X. Wang, B. Su, H.G. Lee, X. Li, G. Perry, M.A. Smith, X. Zhu, Impaired balance of mito-
chondrial ﬁssion and fusion in Alzheimer's disease, J. Neurosci. 29 (2009) 9090–9103.
[77] M. Zaninello, L. Scorrano, Pathogenic mutants of Opa1 decrease axonal mito-
chondria in primary retinal ganglion cells, in: Mitochondrial Dynamics: From
Mechanism to Disease, Sardinia, Italy, 2011.
[78] K.E. White, V. Davies, V. Hogan, M. Piechota, P. Nichols, D.M. Turnbull, M.
Votruba, OPA1 deﬁciency is associated with increased autophagy in retinal gan-
glion cells in a murine model of dominant optic atrophy, Invest. Ophthalmol. Vis.
Sci. 50 (2009) 2567–2571.
[79] G. Twig, A. Elorza, A.J. Molina, H. Mohamed, J.D. Wikstrom, G. Walzer, L. Stiles,
S.E. Haigh, S. Katz, G. Las, J. Alroy, M. Wu, B.F. Py, J. Yuan, J.T. Deeney, B.E.
Corkey, O.S. Shirihai, Fission and selective fusion govern mitochondrial segrega-
tion and elimination by autophagy, EMBO J. 27 (2008) 433–446.
[80] L.C. Gomes, G. Di Benedetto, L. Scorrano, During autophagymitochondria elongate, are
spared from degradation and sustain cell viability, Nat. Cell Biol. 13 (2011) 589–598.
[81] R. Lodi, C. Tonon, M.L. Valentino, S. Iotti, V. Clementi, E. Malucelli, P. Barboni, L.
Longanesi, S. Schimpf, B. Wissinger, A. Baruzzi, B. Barbiroli, V. Carelli, Deﬁcit of
in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy,
Ann. Neurol. 56 (2004) 719–723.
[82] R. Lodi, C. Tonon, M.L. Valentino, D. Manners, C. Testa, E. Malucelli, C. La Morgia,
P. Barboni, M. Carbonelli, S. Schimpf, B. Wissinger, M. Zeviani, A. Baruzzi, R.
Liguori, B. Barbiroli, V. Carelli, Defective mitochondrial adenosine triphosphate
production in skeletal muscle from patients with dominant optic atrophy due
to OPA1 mutations, Arch. Neurol. 68 (2011) 67–73.
[83] P. Yu-Wai-Man, M.I. Trenell, K.G. Hollingsworth, P.G. Grifﬁths, P.F. Chinnery,
OPA1 mutations impair mitochondrial function in both pure and complicated
dominant optic atrophy, Brain 134 (2011) e164.
[84] P. Yu-Wai-Man, K.S. Sitarz, D.C. Samuels, P.G. Grifﬁths, A.K. Reeve, L.A. Bindoff, R.
Horvath, P.F. Chinnery, OPA1 mutations cause cytochrome c oxidase deﬁciency
due to loss of wild-typemtDNAmolecules, Hum.Mol. Genet. 19 (2010) 3043–3052.
[85] N.J. Van Bergen, J.G. Crowston, L.S. Kearns, S.E. Stafﬁeri, A.W. Hewitt, A.C. Cohn,
D.A. Mackey, I.A. Trounce, Mitochondrial oxidative phosphorylation compensa-
tion may preserve vision in patients with OPA1-linked autosomal dominant
optic atrophy, PLoS One 6 (2011) e21347.
[86] Y. Nochez, S. Arsene, N. Gueguen, A. Chevrollier, M. Ferre, V. Guillet, V. Desquiret,
A. Toutain, D. Bonneau, V. Procaccio, P. Amati-Bonneau, P.J. Pisella, P. Reynier,
Acute and late-onset optic atrophy due to a novel OPA1 mutation leading to a
mitochondrial coupling defect, Mol. Vis. 15 (2009) 598–608.
[87] V.I. Mayorov, A.J. Lowrey, V. Biousse, N.J. Newman, S.D. Cline, M.D. Brown, Mito-
chondrial oxidative phosphorylation in autosomal dominant optic atrophy, BMC
Biochem. 9 (2008) 22.
[88] K. Aure, G. Fayet, J.P. Leroy, E. Lacene, N.B. Romero, A. Lombes, Apoptosis in mi-
tochondrial myopathies is linked to mitochondrial proliferation, Brain 129
(2006) 1249–1259.
[89] J.Y. Kim, J.M. Hwang, H.S. Ko, M.W. Seong, B.J. Park, S.S. Park, Mitochondrial DNA
content is decreased in autosomal dominant optic atrophy, Neurology 64 (2005)
966–972.
[90] T. Kanazawa, M.D. Zappaterra, A. Hasegawa, A.P. Wright, E.D. Newman-Smith,
K.F. Buttle, K. McDonald, C.A. Mannella, A.M. van der Bliek, The C. elegans Opa1
homologue EAT-3 is essential for resistance to free radicals, PLoS Genet. 4
(2008) e1000022.
[91] W. Yarosh, J. Monserrate, J.J. Tong, S. Tse, P.K. Le, K. Nguyen, C.B. Brachmann, D.C.
Wallace, T. Huang, The molecular mechanisms of OPA1-mediated optic atrophy
in Drosophila model and prospects for antioxidant treatment, PLoS Genet. 4
(2008) e6.
[92] S. Tang, P.K. Le, S. Tse, D.C. Wallace, T. Huang, Heterozygous mutation of Opa1 in
Drosophila shortens lifespan mediated through increased reactive oxygen spe-
cies production, PLoS One 4 (2009) e4492.[93] P. Shahrestani, H.T. Leung, P.K. Le, W.L. Pak, S. Tse, K. Ocorr, T. Huang, Heterozy-
gous mutation of Drosophila Opa1 causes the development of multiple organ ab-
normalities in an age-dependent and organ-speciﬁc manner, PLoS One 4 (2009)
e6867.
[94] P.A. Williams, J.E. Morgan, M. Votruba, Mouse models of dominant optic atro-
phy: what do they tell us about the pathophysiology of visual loss? Vision Res.
51 (2011) 229–234.
[95] B.A. Moore, G.D. Gonzalez Aviles, C.E. Larkins, M.J. Hillman, T. Caspary, Mito-
chondrial retention of Opa1 is required for mouse embryogenesis, Mamm. Ge-
nome 21 (2010) 350–360.
[96] P.A. Williams, J.E. Morgan, M. Votruba, Opa1 deﬁciency in a mouse model of
dominant optic atrophy leads to retinal ganglion cell dendropathy, Brain 133
(2010) 2942–2951.
[97] P.A. Williams, M. Piechota, C. von Ruhland, E. Taylor, J.E. Morgan, M. Votruba,
Opa1 is essential for retinal ganglion cell synaptic architecture and connectivity,
Brain 135 (2012) 493–505.
[98] A.R. Barnard, P. Charbel Issa, G. Perganta, P.A. Williams, V.J. Davies, S. Sekaran, M.
Votruba, R.E. MacLaren, Speciﬁc deﬁcits in visual electrophysiology in a mouse
model of dominant optic atrophy, Exp. Eye Res. 93 (2011) 771–777.
[99] P. Heiduschka, S. Schnichels, N. Fuhrmann, S. Hofmeister, U. Schraermeyer, B.
Wissinger, M.V. Alavi, Electrophysiological and histologic assessment of retinal
ganglion cell fate in a mouse model for OPA1-associated autosomal dominant
optic atrophy, Invest. Ophthalmol. Vis. Sci. 51 (2010) 1424–1431.
[100] P. Yu-Wai-Man, M. Bailie, A. Atawan, P.F. Chinnery, P.G. Grifﬁths, Pattern of ret-
inal ganglion cell loss in dominant optic atrophy due to OPA1 mutations, Eye
(Lond.) 25 (2011) 596–602.
[101] Z. Zhang, N. Wakabayashi, J. Wakabayashi, Y. Tamura, W.J. Song, S. Sereda, P.
Clerc, B.M. Polster, S.M. Aja, M.V. Pletnikov, T.W. Kensler, O.S. Shirihai, M.
Iijima, M.A. Hussain, H. Sesaki, The dynamin-related GTPase Opa1 is required
for glucose-stimulated ATP production in pancreatic beta cells, Mol. Biol. Cell
22 (2011) 2235–2245.
[102] G.W. Dorn II, C.F. Clark, W.H. Eschenbacher, M.Y. Kang, J.T. Engelhard, S.J.
Warner, S.J. Matkovich, C.C. Jowdy, MARF and Opa1 control mitochondrial and
cardiac function in Drosophila, Circ. Res. 108 (2011) 12–17.
[103] J. Piquereau, F. Cafﬁn, M. Novotova, A. Prola, A. Garnier, P. Mateo, D. Fortin, H. Huynh
le, V. Nicolas, M.V. Alavi, C. Brenner, R. Ventura-Clapier, V. Veksler, F. Joubert,
Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function,
and cardiac adaptation to pressure overload, Cardiovasc. Res. 94 (2012) 408–417.
[104] L. Chen, Q. Gong, J.P. Stice, A.A. Knowlton, Mitochondrial OPA1, apoptosis, and
heart failure, Cardiovasc. Res. 84 (2009) 91–99.
[105] G. Pidoux, O. Witczak, E. Jarnaess, L. Myrvold, H. Urlaub, A.J. Stokka, T. Kuntziger,
K. Tasken, Optic atrophy 1 is an A-kinase anchoring protein on lipid droplets
that mediates adrenergic control of lipolysis, EMBO J. 30 (2011) 4371–4386.
[106] T.C. Walther, R.V. Farese Jr., Lipid droplets and cellular lipid metabolism, Annu.
Rev. Biochem. 81 (2012) 687–714.
[107] O.M. de Brito, L. Scorrano, Mitofusin 2 tethers endoplasmic reticulum to mito-
chondria, Nature 456 (2008) 605–610.
[108] M. Schrader, N.A. Bonekamp, M. Islinger, Fission and proliferation of peroxi-
somes, Biochim. Biophys. Acta 1822 (2012) 1343–1357.
[109] S. Murphy, S. Martin, R.G. Parton, Lipid droplet-organelle interactions; sharing
the fats, Biochim. Biophys. Acta 1791 (2009) 441–447.
[110] J. Pu, C.W. Ha, S. Zhang, J.P. Jung, W.K. Huh, P. Liu, Interactomic study on interac-
tion between lipid droplets and mitochondria, Protein Cell 2 (2011) 487–496.
[111] H. Wang, U. Sreenevasan, H. Hu, A. Saladino, B.M. Polster, L.M. Lund, D.W. Gong,
W.C. Stanley, C. Sztalryd, Perilipin 5, a lipid droplet-associated protein, provides
physical andmetabolic linkage tomitochondria, J. Lipid Res. 52 (2011) 2159–2168.
[112] H. Zhang, Y. Wang, J. Li, J. Yu, J. Pu, L. Li, S. Zhang, G. Peng, F. Yang, P. Liu, Prote-
ome of skeletal muscle lipid droplet reveals association with mitochondria and
apolipoprotein a-I, J. Proteome Res. 10 (2011) 4757–4768.
[113] J.M. Goodman, The gregarious lipid droplet, J. Biol. Chem. 283 (2008) 28005–28009.
[114] M. Wasilewski, M. Semenzato, S.M. Rafelski, J. Robbins, A.I. Bakardjiev, L.
Scorrano, Optic atrophy 1-dependent mitochondrial remodeling controls ste-
roidogenesis in trophoblasts, Curr. Biol. 22 (2012) 1228–1234.
[115] D.V. Jeyaraju, A. Sood, A. Laforce-Lavoie, L. Pellegrini, Rhomboid proteases in mito-
chondria and plastids: Keeping organelles in shape, Biochim. Biophys, Acta. (2012)
May 24. [Electronic publication ahead of print].
